1 Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005; 26: 78–113
2 Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364–7
3 Brossard JH, Cloutier M, Roy L, et al. Accumulation of a non- (1–84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81: 3923–9
4 Brossard JH, Lepage R, Cardinal H, et al. Influence of glomerular filtration rate on non-(1–84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000; 46: 697–703
5 D’Amour P, Brossard JH, Rousseau L, et al. Structure of non-(1–84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68: 998–1007
6 Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006; 52: 1771–6
7 Sturgeon CM, Ellis AR, Al-Sadie R. UK NEQAS [Edinburgh], Annual Review 2004. Report available on request from UK NEQAS (Edinburgh)
8 Renal Association. Treatment of Adults and Children with Renal Failure: Standards and Audit Measures. 3rd Edn. London: Royal College of Physicians of London and the Renal Association, 2002
9 Sturgeon CM, Ellis AR, Al-Sadie R. UK NEQAS [Edinburgh], Annual Review 2005. Report available on request from UK NEQAS (Edinburgh)
10 Ansell D, Feest T, eds. UK Renal Registry Report 2004
11 Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1–201
12 National Institute for Health and Clinical Excellence. Appraisal Consultation Document: cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Available at http:// www.nice.org.uk/page.aspx?o=353192 (accessed 10 October 2006)
13 Joint Specialty Committee on Renal Medicine of the Royal College of Physicians and the Renal Association, and the Royal College of General Practitioners. Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral. London: Royal College of Physicians, 2006. Available at http://www.renal. org/CKDguide/full/CKDprintedfullguide.pdf (accessed 10 October 2006)
14 Chang JM, Lin SP, Kuo HT, et al. 7–84 Parathyroid hormone fragments are proportionally increased with the severity of uremic hyperparathyroidism. Clin Nephrol 2005; 63: 351–5
15 Coen G, Bonucci E, Ballanti P, et al. PTH 1–84 and PTH ‘7–84’ in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348–54
16 Tsuchida T, Ishimura E, Hirowatari K, et al. Serum levels of 1–84 and 7–84 parathyroid hormone in predialysis patients with chronic renal failure measured by the intact and bio-PTH assay. Nephron Clin Pract 2006; 102: c108–14
17 Godber IM, Parker CR, Lawson N, et al. Comparison of intact and ‘whole molecule’ parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy. Ann Clin Biochem 2002; 39: 314–7
18 Blumsohn A, Al Hadari A. Parathyroid hormone: what are we measuring and does it matter? Ann Clin Biochem 2002; 39: 169–72
Answers to all your Biology Questions
